Issues

• Sub-optimal therapy may increase prevalence of resistance and/or lead to clinical failures

  • Marginally effective compounds (PK/PD)
  • Fluoroquinolone active but either not being absorbed or patient non-compliant

Previous slide

Next slide

Back to first slide

View graphic version